Insilico Medicine-led study combines quantum computing and generative AI for drug discovery
Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it combined two rapidly developing technologies, quantum computing and generative AI, to explore lead candidate discovery in drug development and successfully demonstrated the potential advantages of quantum generative adversarial networks in generative chemistry.
The study, published May 13 in the American Chemical Society’s Journal of Chemical Information and Modeling, a leading journal in computational modeling, was led by Insilico’s Taiwan and UAE centers which focus on pioneering ...










